Thirty Years On, Quo Vadis Cancer Companion Diagnostics?

News

The concept of companion diagnostics for cancer was introduced in 1998 with approval of trastuzumab (Herceptin®) together with the respective HER2 test for selecting patients most likely to benefit.

View PDF